title: Spironolactone may reduce the risk of incident rosacea.
authors.affiliation: Basel Pharmacoepidemiology Unit, Division of Clinical Pharmacy and Epidemiology, Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland; Hospital Pharmacy, University Hospital Basel, Basel, Switzerland.
authors.forename: Julia
authors.initials: J
authors.lastname: Spoendlin
authors.affiliation: Galderma Research and Development, Sophia Antipolis, France.
authors.forename: Johannes J
authors.initials: JJ
authors.lastname: Voegel
authors.affiliation: Boston Collaborative Drug Surveillance Program, Boston University, Lexington, Massachusetts, USA.
authors.forename: Susan S
authors.initials: SS
authors.lastname: Jick
authors.affiliation: Basel Pharmacoepidemiology Unit, Division of Clinical Pharmacy and Epidemiology, Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland; Hospital Pharmacy, University Hospital Basel, Basel, Switzerland; Boston Collaborative Drug Surveillance Program, Boston University, Lexington, Massachusetts, USA. Electronic address: christoph.meier@usb.ch.
authors.forename: Christoph R
authors.initials: CR
authors.lastname: Meier
mesh_terms: D016208:Databases, Factual; D004232:Diuretics / Q000627:therapeutic use; D005260:Female; D006801:Humans; D015994:Incidence; D008297:Male; D012307:Risk Factors; D012393:Rosacea / Q000453:epidemiology* / Q000517:prevention & control*; D013148:Spironolactone / Q000627:therapeutic use*
chemical_list: D004232:Diuretics; D013148:Spironolactone